title: Progressive ocular inflammation following anti-tubercular therapy for presumed ocular tuberculosis in a high-endemic setting.
abstract: OBJECTIVE
  To analyze the incidence and clinical course of patients developing progressive ocular inflammation following anti-tubercular therapy (ATT) for presumed ocular tuberculosis (TB).
  
  
  METHODS
  Retrospective analysis of medical records of patients who received ATT for presumed ocular TB and completed at least 12 months follow-up after initiation of ATT. The diagnosis of presumed ocular TB was based on presence of ocular signs suggestive of TB, evidence of past tubercular infection, and exclusion of mimicking clinical entities. All patients received a combination of ATT and corticosteroid therapy. Primary outcome measure was progression (worsening) of ocular inflammation, defined as a two-step increase in level of inflammation (anterior chamber/ vitreous) or the appearance of new lesions following initiation of ATT.
  
  
  RESULTS
  A total of 106 patients (64 male, 42 female) received ATT for presumed ocular TB. Twenty-six (24.5%) patients developed progressive intraocular inflammation following ATT. Primary diagnoses in these patients were: anterior uveitis (n=1), intermediate uveitis (n=9), retinal vasculitis (n=3), serpiginous-like choroiditis (n=7), multifocal choroiditis (n=2), and pan-uveitis (n=4). Following progressive inflammation, diagnosis was revised in two patients (7.7%)-both responded to alternative therapy. Of the rest, majority (n=16; 61.5%) resolved with escalation of corticosteroid therapy. Five patients (19.2%)-all having intermediate uveitis-required therapeutic vitrectomy for resolution. Three patients (11.5%) had persistent inflammation at end of follow-up period.
  
  
  CONCLUSIONS
  Progressive inflammation following ATT for presumed ocular TB is common. It generally resolves on escalation of corticosteroid therapy. Cases not responding to increased immunosuppression need to be re-investigated to rule out a nontubercular cause.
authors: L V Prasad Eye Institute, Bhubaneswar, India. eyetalk@gmail.com
authors: S
authors: S
authors: Basu
authors: S
authors: S
authors: Nayak
authors: T R
authors: TR
authors: Padhi
authors: T
authors: T
authors: Das
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use*; D002648:Child; D002833:Choroiditis / Q000453:epidemiology / Q000209:etiology; D018450:Disease Progression; D005128:Eye Diseases / Q000453:epidemiology* / Q000209:etiology; D005260:Female; D006801:Humans; D015994:Incidence; D007194:India / Q000453:epidemiology; D007249:Inflammation / Q000453:epidemiology / Q000209:etiology; D008297:Male; D008875:Middle Aged; D031300:Retinal Vasculitis / Q000453:epidemiology / Q000209:etiology; D012189:Retrospective Studies; D014392:Tuberculosis, Ocular / Q000150:complications / Q000188:drug therapy*; D014605:Uveitis / Q000453:epidemiology / Q000209:etiology; D055815:Young Adult
chemical_list: D000305:Adrenal Cortex Hormones; D000995:Antitubercular Agents